opnMe by Boehringer Ingelheim

BLC6 degrader

BI-3802

Boehringer Ingelheim

Table of contents

Summary

BI-3802 is a single digit nanomolar BCL6::Co-repressor inhibitor which induces efficacious BCL6 protein degradation in several DLBCL cell lines.

Chemical Structure



Figure 1: 2D structure of BI-3802, a BCL6 degrader



Figure 2: BI-3802, 3D conformation, as observed in complex with BCL6 by X-ray crystallography

Highlights

BI-3802 is a highly potent B-cell lymphoma 6 (BCL6) inhibitor. It inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors *in vitro* as well as in a cellular context. In addition, BI-3802 was found to be a potent and efficacious degrader of the BCL6 protein in many DLBCL cell lines[1]. Its good permeability and unprecedented protein degradation effects make this compound an ideal tool to study BCL6 biology *in vitro*.

Target information

B-cell lymphoma 6 (BCL6) functions as a transcriptional repressor that binds specific DNA sequences *via* its Zn-fingers and recruits transcriptional co-repressors (e.g. BCOR, SMRT, NCOR) by its BTB/POZ domain[2]. BCL6 is essential for the germinal center (GC) reaction[3]. It represses a broad set of genes that are required to sustain mutagenic activity without activating the DNA damage response or apoptosis[4]. BCL6 also prevents maturation to plasma or memory cells and helps to maintain a de-differentiated state. Its expression must be switched off to allow the B-cell to exit the GC cycle and differentiate. BCL6 is a known oncogenic driver and frequently overexpressed in DLBCL[5,6].



Figure 3: BCL6-BTB dimer with BI-3802, as observed by X-ray[1]. BI-3802 binds at the interface of two monomers (monomers are shown in green and grey).

In vitro activity

BI-3802 displays an $IC_{50} \leq 3$ nM in a BCL6::BCOR U*Light* TR-FRET assay and degrades BCL6 protein with a DC_{50} of 20 nM (in SU-DHL-4 cell lines)[1].

It also inhibits the BCL6::Co-repressor complex formation with an IC_{50} of 43 nM.

It is recommended to store and use 1 mM DMSO stock solutions of BI-3802 for all *in vitro* experiments.

PROBE NAME / NEGATIVE CONTROL	BI-3802	BI-5273
MW [Da, free base][a]	484.9	500.0
BCL6::BCOR U*light* TR-FRET (IC_{50}) [nM][b]	≤3	10,162
BCL6::NCOR LUMIER (IC_{50}) [nM]	43	n.d.
BCL6 protein degradation (IC_{50}) [nM][c]	20	*Inactive*

[a] For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs
[b] With affinities of approximately 3 nM, the assay wall of this assay is reached, limiting the accuracy of the biochemical assay.
[c] In SU-DHL-4 cells

In vitro DMPK and CMC parameters

PROBE NAME / NEGATIVE CONTROL	BI-3802	BI-5273
log D @ pH 11	4.62	1.63
Solubility @ pH 6.8 [µg/mL]	<1	84
Caco-2 permeability AB @ pH 7.4 [$*10^{-6}$ cm/s]	8.5	22
Caco-2 efflux ratio	0.4	0.6
Human hepatocyte clearance [% Q_H]	56	n.d.
Plasma Protein Binding human [%]	99.95	n.d.

In vivo DMPK parameters

BI-3802 showed poor bioavailability after *p.o.* administration in mice (see table).

PROBE NAME	BI-3802	
Dose [mg/kg]	10	100
AUC [nM/h]	1,856	4,635
C_{max} [nM]	193	597
t_{max} [h]	2	4.6

Negative control

BI-5273 is a close analog of BI-3802 which binds only very weakly to the BCL6 BTB domain (IC_{50} ~ 10 µM) and does not induce protein degradation.



Figure 4: BI-5273 which serves as a negative control

Selectivity

SELECTIVITY DATA AVAILABLE	BI-3802	BI-5273
SafetyScreen44™ with kind support of eurofins	Yes	Yes
Invitrogen®	Yes	No
DiscoverX®	No	No
Dundee	No	No

Co-crystal structure of the BI probe compound and the target protein

The X-ray crystal structure of BCL6 in complex with BI-3802 is available (PDB code: 5MW2)[1].

Reference molecule(s)

Several small molecule BCL6 inhibitors have been published recently[7,8,9,10]. None of those is described as a BCL6 protein degrader.

Supplementary data

Selectivity data can be downloaded free of charge from opnMe.

References

1. Kerres N., Steurer S., Schlager S., Bader G., Berger H., Caligiuri M., Dank C., Engen J. R., Ettmayer P., Fischerauer B., Flotzinger G., Gerlach D., Gerstberger T., Gmaschitz T., Greb P., Han B., Heyes E., Iacob R. E., Kessler D., Kölle H., Lamarre L., Lancia D. R., Lucas S., Mayer M., Mayr K., Mischerikow N., Mück K., Peinsipp C., Petermann O., Reiser U., Rudolph D., Rumpel K., Salomon C., Scharn D., Schnitzer R., Schrenk A., Schweifer N., Thompson D., Traxler E., Varecka R., Voss T., Weiss-Puxbaum A., Winkler S., Zheng X., Zoephel A., Kraut N., McConnell D., Pearson M., Koegl M. Chemically induced degradation of the oncogenic transcription factor BCL6 *Cell Rep.* **2017**, 20(12), 2860-2875. DOI: 10.1016/j.celrep.2017.08.081, PubMed.

2. Zollman S., Godt D., Privé G. G., Couderc J. L., Laski F. A. The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila *Proc. Natl. Acad. Sci. U S A* **1994**, 91, 10717-10721. DOI:10.1073/pnas.91.22.10717, PubMed.

3. Dent A. L., Shaffer A. L., Yu X., Allman D., Staudt L. M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6 *Science* **1997**, *276*, 589-592. DOI: 10.1126/science.276.5312.589, PubMed.

4. Basso K., Saito M., Sumazin P., Margolin A. A., Wang K., Lim W.-K., Kitagawa Y., Schneider C., Alvarez M. J., Califano A., Dalla-Favera R. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells *Blood* **2010**, *115*, 975-984. DOI: 10.1182/blood-2009-06-227017, PubMed.

5. Basso K., Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells *Immunol. Rev.* **2012**, *247*, 172-183. DOI: 10.1111/j.1600-065X.2012.01112.x, PubMed.

6. Hatzi K., Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis *Trends Mol. Med.* **2014**, *20*, 343-352. DOI:10.1016/j.molmed.2014.03.001, PubMed.

7. Cardenas M. G., Yu W., Beguelin W., Teater M. R., Geng H., Goldstein R. L., Oswald E., Hatzi K., Yang S.-N., Cohen J., Shaknovich R., Vanommeslaeghe K., Cheng H., Liang D., Cho H. J., Abbott J., Tam W., Du W., Leonard J. P., Elemento O., Cerchietti L., Cierpicki T., Xue F., MacKerell Jr A. D., Melnick A. M. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma *J. Clin. Invest.* **2016**, *126*, 3351-3362. DOI: 10.1172/JCI85795, PubMed.

8. McCoull W., Abrams R. D., Anderson E., Blades K., Barton P., Box M., Burgess J., Byth K., Cao Q., Chuaqui C., Carbajo R. J., Cheung T., Code E., Ferguson A. D., Fillery S., Fuller N. O., Gangl E., Gao N., Grist M., Hargreaves D., Howard M. R., Hu J., Kemmitt P. D., Nelson J. E., O'Connell N., Prince D. B., Raubo P., Rawlins P. B., Robb G. R., Shi J., Waring M. J., Whittaker D., Wylot M., Zhu X. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors *J. Med. Chem.* **2017**, *60*, 4386-4402. DOI: 10.1021/acs.jmedchem.7b00359, PubMed.

9. Kamada Y., Sakai N., Sogabe S., Ida K., Oki H., Sakamoto K., Lane W., Snell G., Iida M., Yasuhiro I., Sakamoto J., Matsui J. Discovery of a B-cell lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-driven Fragment-based Approach *J. Med. Chem.* **2017**, *60*, 4358-4368. DOI: 10.1021/acs.jmedchem.7b00313, PubMed.

10. Yasui T., Yamamoto T., Sakai N., Asano K., Takai T., Yoshitomi Y., Davis M., Takagi T., Sakamoto K., Sogabe S., Kamada Y., Lane W., Snell G., Iwata M., Goto M., Inooka H., Sakamoto J.-I., Nakada Y., Imaeda Y. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design *Bioorg. Med. Chem.* **2017**, *25*, 4876-4886. DOI: 10.1016/j.bmc.2017.07.037, PubMed.